Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Drops By 98.1%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a large drop in short interest in October. As of October 31st, there was short interest totalling 100 shares, a drop of 98.1% from the October 15th total of 5,200 shares. Based on an average trading volume of 13,200 shares, the short-interest ratio is presently 0.0 days.

SAB Biotherapeutics Price Performance

Shares of SAB Biotherapeutics stock traded up $0.00 during trading on Wednesday, hitting $0.05. 3,789 shares of the stock traded hands, compared to its average volume of 19,583. The firm’s fifty day moving average is $0.04 and its 200-day moving average is $0.04. SAB Biotherapeutics has a 52 week low of $0.01 and a 52 week high of $0.19.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.